BrightSpring (BTSG) Q1 2026 earnings review
Record Margins and Deleveraging Drive Guidance Raise
BrightSpring delivered an exceptionally strong Q1, pushing both top and bottom lines higher while significantly cleaning up its balance sheet. Adjusted EBITDA growth of 45% vastly outpaced the 26% revenue growth, proving that operating leverage is kicking in. The standout dynamic was in Pharmacy Solutions: a massive shift toward higher-margin specialty drugs pushed gross profit per script up 50% year-over-year. Furthermore, the closing of the Community Living divestiture slashed net leverage to 2.27x, removing a major debt overhang and giving management ample dry powder. Consequently, the company raised its full-year 2026 guidance across all major metrics.
🐂 Bull Case
Gross profit per script jumped 50% YoY. BrightSpring's pivot toward Limited Distribution Drugs (LDDs) and specialty pharmacy is highly accretive, driving total company adjusted EBITDA up 45%.
Net leverage plummeted to 2.27x, down from 4.16x at the end of 2024. The $31.2 million gain from the Community Living sale and strong free cash flow completely changes the company's risk profile.
🐻 Bear Case
Despite revenue surging, actual prescriptions dispensed declined 1% YoY. Relying entirely on price and specialty mix masks underlying volume weakness in the broader pharmacy network.
The Amedisys/LHC branch acquisition added significant volume (ADC up 52%), but these assets carry a lower historical margin profile, requiring flawless execution to bring them up to corporate standards.
⚖️ Verdict: 🟢
Bullish. The combination of accelerating EBITDA margins, rapid deleveraging, and an immediate guidance raise signals a business firing on all cylinders, even if core pharmacy script volumes are flat.
Key Themes
Specialty Pharmacy Profitability Surging
The Pharmacy Solutions segment is seeing an Accelerating profitability trend. Revenue per script grew 27% to $295.56, and gross profit per script spiked 50% to $28.03. This indicates a highly successful mix shift toward complex, high-margin Limited Distribution Drugs (LDDs) and specialty infusions, completely decoupling profit growth from base volume growth.
Core Script Volume Contraction
A specific data point contradicts the pure growth narrative: total prescriptions dispensed actually Decelerated, falling 1% YoY (10.73 million vs 10.88 million). While specialty pricing is currently papering over this decline, a shrinking base of core home and community pharmacy customers limits long-term cross-selling opportunities and creates vulnerability if specialty pricing power wanes.
Provider Services Volume Scaling via M&A
The Provider Services segment is Accelerating, driven by the closing and integration of the Amedisys and LHC branches. Home Health Care average daily census (ADC) rocketed 52% YoY to 46,066. Rehab Care persons served grew 14% to 7,620. This acquired scale makes BrightSpring an essential partner for payers.
AI and Operational Automation Yielding Leverage
Management's past investments in AI-driven route optimization, automated scheduling, and centralized lean procurement are generating tangible results. SG&A as a percentage of revenue dropped to 10.0% in 26Q1 from 12.5% in 25Q1. This technology-driven efficiency is acting as a permanent structural tailwind to margins.
Rapid Deleveraging Accomplished
The balance sheet transformation is Reversing from a liability to a strength. With the Community Living divestiture officially closed to Sevita (netting a $31.2M gain), net leverage sits at an exceptionally healthy 2.27x. This easily beats management's previous target of 2.5x, drastically lowering future interest expense.
Impending IRA Headwinds
From a macro perspective, the impending rollout of the Inflation Reduction Act (IRA) drug pricing provisions remains a dark cloud. Management previously warned of a potential ~$400M revenue headwind in 2026 tied to specialty/infusion drugs and brand-to-generic conversions. Given the company's increasing reliance on specialty margins, this macro policy shift poses a severe second-half execution risk.
M&A Margin Dilution in Provider Services
While Provider volume surged, segment EBITDA margins are Stable to Decelerating sequentially. Provider segment EBITDA was 14.9% ($66M on $442M revenue), down from 16.2% in 25Q4. The acquired Amedisys assets carry a lower historical margin profile, putting the burden on management to aggressively cut redundant costs to restore peak segment profitability.
Other KPIs
Accelerating. Up 21% YoY from $101.6 million. Even backing out $21.5 million in CapEx, Free Cash Flow remains solidly above $100M for the quarter. This cash generation, combined with divestiture proceeds, fully funded the $60M secondary offering share repurchase in March.
Decelerating profitability impact. Corporate overhead grew 25% YoY from $36 million in 25Q1, scaling perfectly in line with total revenue (25.6%). This indicates that back-office expenses are being managed effectively as the company integrates its recent acquisitions.
Guidance
Accelerating. The midpoint of $14.975B implies a 16.0% YoY growth over FY25's $12.91B. This is a deliberate raise from the prior preliminary guide of $14.45B - $15.0B, reflecting stronger-than-expected Q1 performance in Pharmacy pricing and successful Amedisys asset integration.
Accelerating. The midpoint of $810M implies a 31.1% YoY surge over FY25's $618M. This massive margin expansion guide proves management expects the highly profitable specialty pharmacy mix shift to persist through the end of the year, alongside a projected ~$30M contribution from Amedisys/LHC.
Accelerating. Raised from the prior $12.6B-$13.1B range, implying roughly 14% YoY growth. The lack of volume growth implies this will be achieved almost exclusively through price realization and generic/specialty mix.
Accelerating. Implies approximately 29.7% YoY growth. This reflects the inorganic bump from the newly acquired branches, stepping up from the mid-teens organic growth rates seen in 2025.
Key Questions
Sustainability of Pharmacy Profitability
Gross profit per script spiked 50% year-over-year while volume fell 1%. How much of this profitability jump is due to one-time generic conversion events versus permanent structural improvements in LDD contracting?
Capital Allocation Post-Deleveraging
With net leverage now at 2.27x—well below your historical target of 2.5x—does the capital allocation strategy pivot heavily toward additional share repurchases, or are there larger M&A targets on the horizon?
Provider Margin Integration Timeline
Provider segment EBITDA margin dipped sequentially to 14.9%. What is the precise timeline for integrating the Amedisys/LHC branches and bringing them up to the legacy Provider margin profile of 16-17%?
IRA Revenue Defense
You previously flagged a potential ~$400 million revenue headwind for 2026 related to the IRA and generic conversions in Specialty/Infusion. Have your mitigation strategies evolved to fully absorb this, or is this still a looming risk for the second half of the year?